What Goldman Sachs is saying about the CSL (ASX:CSL) share price after its R&D update

Last week was a reasonably disappointing one for the CSL Limited (ASX: CSL) share price.

Despite releasing its research and development (R&D) update for 2021, the biotherapeutics company’s shares ended the period with a weekly decline of 0.5%.

What was the reaction…